Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Meg 21

Meg 21
1997 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$458K LATEST DEAL AMOUNT
6 INVESTORS
Description

Developer skincare products designed to treat ageing skin. The company's products are made with proprietary small molecule drugs that inhibit a novel enzymatic pathway that causes the formation of a highly reactive sugar, 3-deoxyglucosone, that stimulates the production of Advanced Glycation End Products (AGEs), oxidative stress and a cascade of inflammatory cytokines, enabling users to use clinically validated and cosmetically elegant cosmetic products that support healthy cellular function.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Personal Products
Pharmaceuticals
Primary Office
  • 261 Old York Road
  • Suite 427
  • Jenkintown, PA 19046
  • United States

+1 (877) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Meg 21’s full profile, request a free trial.

Meg 21 Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 30-Aug-2018 $458K 000.00 Completed Generating Revenue
9. Later Stage VC 13-Jun-2018 00000 000.00 Completed Generating Revenue
8. Later Stage VC 00.00 000.00 Completed Generating Revenue
7. Seed Round 03-Feb-2016 00.00 Completed Generating Revenue
6. Grant 27-Jul-2010 00.00 Completed Generating Revenue
5. Angel (individual) 27-Jul-2010 00000 00.00 Completed Generating Revenue
4. Corporate 19-Jun-2006 00.00 00.00 Completed Generating Revenue
3. Seed Round 12-Oct-1998 00000 00000 Completed Startup
2. Grant 01-Jan-1997 $100K Completed Startup
1. Joint Venture 01-Jan-1997 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Meg 21 Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
National Institutes of Health Government Minority 000 0000 000000 0
Rohto Pharmaceuticals Corporation Minority 000 0000 000000 0
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
Fox Chase Cancer Center Corporation Majority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Meg 21 Executive Team (6)

Name Title Board
Seat
Contact
Info
Annette Tobia Ph.D Co-Founder, Chief Executive Officer & Board Member
John Favreau President
Kevin Kimmel Director, Corporate Secretary and Treasurer
Frank Kappler Ph.D Co-Founder and Scientist
David Smith Executive Chairman & Board Member

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

Meg 21 Board Members (2)

Name Representing Role Since Contact
Info
Annette Tobia Ph.D Meg 21 Co-Founder, Chief Executive Officer & Board Member 000 0000
David Smith Meg 21 Executive Chairman & Board Member 000 0000